Home/Filings/4/0001104659-24-101112
4//SEC Filing

EISWIRTH RICHARD S JR 4

Accession 0001104659-24-101112

CIK 0001267602other

Filed

Sep 17, 8:00 PM ET

Accepted

Sep 18, 9:53 PM ET

Size

28.3 KB

Accession

0001104659-24-101112

Insider Transaction Report

Form 4
Period: 2024-09-16
Transactions
  • Disposition to Issuer

    Common Stock

    2024-09-16324,0180 total
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2024-09-16325,0000 total
    Exercise: $1.18Exp: 2027-01-19Common Stock (325,000 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2024-09-1614,7000 total
    Common Stock (14,700 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2024-09-16400,0000 total
    Exercise: $2.99Exp: 2033-10-01Common Stock (400,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2024-09-1675,0000 total
    Exercise: $4.96Exp: 2032-01-03Common Stock (75,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2024-09-1652,5000 total
    Exercise: $5.01Exp: 2031-01-06Common Stock (52,500 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2024-09-16300,0000 total
    Exercise: $1.16Exp: 2028-01-21Common Stock (300,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2024-09-1651,4710 total
    Exercise: $1.33Exp: 2026-10-12Common Stock (51,471 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2024-09-1653,5000 total
    Exercise: $6.75Exp: 2030-01-09Common Stock (53,500 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2024-09-16500,0000 total
    Exercise: $0.86Exp: 2029-01-22Common Stock (500,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2024-09-16275,0000 total
    Exercise: $2.47Exp: 2026-01-03Common Stock (275,000 underlying)
Footnotes (3)
  • [F1]Pursuant to the Agreement and Plan of Merger, dated as of June 21, 2024 (the "Merger Agreement"), by and among the Issuer, ANI Pharmaceuticals, Inc., a Delaware corporation ("Parent") and ANIP Merger Sub INC., a Delaware corporation and a wholly owned indirect subsidiary of Parent, as of the effective time of the merger (the "Effective Time"), each share of common stock was converted into the right to receive (i) $5.50 in cash, without interest (such amount, the "Closing Cash Consideration") and (ii) one contingent value right ("CVR") representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between Parent and a rights agent (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").
  • [F2]Pursuant to the terms of the Merger Agreement, as of the Effective Time, each restricted stock unit (each, an "RSU") granted by the Issuer that was outstanding and unvested immediately prior to the Effective Time was converted into the right to receive (i) an amount of cash equal to the product of (A) the number of shares of common stock then underlying such RSU multiplied by (B) the Closing Cash Consideration and (ii) CVRs in an amount equal to the total number of shares of common stock then underlying such RSUs.
  • [F3]Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option granted by the Issuer to purchase shares (each, an "Option") that was outstanding and unvested immediately prior to the Effective Time vested in full, and each Option that was outstanding and unexercised which had a per share exercise price that was less than the Closing Cash Consideration was converted into the right to receive the sum of an amount in cash (without interest and subject to deduction for any required withholding as contemplated in the Merger Agreement) equal to: (A) the excess, if any, of the Closing Cash Consideration over the exercise price per share of such Option; multiplied by the number of shares underlying such Option and (B) one CVR.

Issuer

ALIMERA SCIENCES INC

CIK 0001267602

Entity typeother

Related Parties

1
  • filerCIK 0001374256

Filing Metadata

Form type
4
Filed
Sep 17, 8:00 PM ET
Accepted
Sep 18, 9:53 PM ET
Size
28.3 KB